FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1762-1763 December 2, 1999 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Wolfe, R. A. PubMed Citation

There is virtual unanimity that the optimal treatment for most patients with end-stage renal disease is renal transplantation. However, unlike the case for liver, heart, and lung transplantation, for which no long-term successful alternative is available, dialysis is also an option in patients with end-stage renal disease, prolonging survival. The benefits of renal transplantation have usually been described in terms of a better quality of life¹ and reduced medical expenses² rather than the prolongation of life. In this issue of the Journal, 27 years after the establishment of federal funding for the treatment of end-stage renal disease and with the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Vianello, A., Spinello, M., Palminteri, G., Brunello, A., Calconi, G., Maresca, M.-C. (2002). Are the baseline chances of survival comparable between the candidates for kidney transplantation who actually receive a graft and those who never get one?. Nephrol Dial Transplant 17: 1093-1098 [Abstract] [Full Text]